Rupert McShane is a consultant at Oxford Health NHS Foundation Trust where he leads a ketamine clinic for depression. He is an Associate Professor in the Department of Psychiatry at University of Oxford. He is an investigator on several ketamine related trials, including trials of esketamine.
Jerry Sanacora is Professor of Psychiatry; Director, Yale Depression Research Program; Co-Director, Yale New Haven Hospital Interventional Psychiatry Service.
He is part of the Yale group which first identified the antidepressant effect of ketamine. He runs both basic science and clinical laboratories. The former uses a chronic stress model to explore cellular and molecular biology. The latter uses novel MRS and pharmacological challenge paradigms. He leads several early phase trials of novel candidate therapies.
Robert Schoevers is Head of Department of Psychiatry
and Director of Research School of Behavioural and Cognitive Neurosciences at
the University of Groningen, Netherlands. His broad research involvement
includes epidemiological and clinical studies
of affective disorders focusing on treatment and prediction of disease
course. He now leads a trial of daily oral esketamine for treatment
Celia Morgan joined Exeter University as Professor of Psychopharmacology in 2013. Previously, she was at UCL, Yale and Melbourne. She is currently researching hippocampal function following heavy ketamine use, neurogenesis and pattern completion in depression, and leads a trial of the effect of IV ketamine and psychotherapy on cognitive function in heavy drinkers (Ketamine for Reduction of Alcoholic Relapse).
Ketamine 2020 is hosted by the NIHR Oxford Health Biomedical Research Centre . We are also grateful for support through Unrestricted Educational Grants from pharmaceutical industry sponsors.
We are committed to reducing the carbon footprint of conferences - hence the substitution of posters with e-Presentations and the pricing of online attendance.